All Infectious disease articles – Page 6
-
NewsP. aeruginosa infection method elucidated with microtissue model
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
-
ArticleRecce Pharmaceuticals’ synthetic approach to combatting AMR
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a ...
-
ArticleEnhancing gene therapy with Circio
In this Q&A, Erik Wiklund, CEO of Circio, explains the key findings of their circVec circular RNA platform technology, why they chose AAV-based gene therapy for AATD as the lead programme, and their plans for the future to enhance the potency and reduce the cost of current gold-standard gene therapy. ...
-
NewsGene editing for HSV-1 shows significant reduction of viral load
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.
-
WhitepaperPoster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
NewsNew findings could influence asthma drug development
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
-
NewsM6A modification is crucial for HIV-1 survival
The discovery of three m6A modifications and their exact locations could lead to the development of drugs that inhibit viral RNA and protein production.
-
NewsExploring the effects of IFNβ in neuroHIV infection
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
-
NewsNew trivalent vaccine for clade 1 sarbecoviruses
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
-
NewsNew AI model could help to overcome antibiotic resistance
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
-
ReportBeyond the lab: vaccine development
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
-
NewsEliminating the HIV virus from infected cells with CRISPR-Cas
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
-
NewsEvaluating novel gene therapies in a whole human liver
Use of the whole liver could revolutionise the development of viral vectors, providing more effective treatments for inherited diseases.
-
NewsEpstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
-
NewsNew insights about the influence of STAP-1 on immune cell activation
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
-
NewsHow successive mRNA vaccines shape T-cell memory
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
-
NewsNew insights into viral-related myocarditis
Understanding heart changes at the molecular level during early infection with adenovirus could enable identification of those at higher risk of arrhythmia.
-
NewsSerum biomarkers for COVID-19 identified
Proteins regulating plasminogen-plasmin levels can be used to identify patients at risk of progressing to a severe stage of COVID-19.
-
NewsIdentification of antibodies to target the NA globular head domain
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.